Jay Stout serves as Chief Technology Officer at Immunovant Inc., where he directs the company's technology strategy and drives innovation in autoimmune disease therapeutics. With more than 20 years in biotechnology, he previously led technology and data science initiatives at Genentech and Amgen, focusing on computational platforms that streamline drug discovery and development. Stout earned advanced degrees in computer science and bioinformatics, building expertise that bridges engineering and life sciences. His career highlights include co-developing AI-enabled target identification systems that have supported multiple clinical candidates and securing patents in immunotechnology and predictive analytics for patient stratification. Stout has authored numerous publications on monoclonal antibody optimization and digital health integration, earning industry recognition for advancing precision approaches in immunology. In his current role, Stout oversees the deployment of advanced analytics, cloud infrastructure, and collaborative tools across Immunovant’s pipeline, enhancing research efficiency for programs in myasthenia gravis, thyroid eye disease, and other indications. His leadership strengthens the company’s ability to translate scientific insights into scalable, patient-focused solutions.